ABHD5 and prostate cancer: We demonstrate that pharmacological activation of ABHD5 with the synthetic ligand SR-3420 robustly suppresses c-MYC protein levels in two castration-resistant prostate cancer models expressing either wild-type or constitutively active, alternatively spliced androgen receptor variants (25).